Early signs from our ongoing trial suggest that people treated with aldesleukin may have better long-term outcomes, including fewer heart attacks. 'If these findings are repeated in a larger trial ...

She said: ‘It is early days, but if further research shows the approach is successful in humans, many people around the world could live well for longer without the need for repeated heart valve ...